how can the panel approve anything when the FDA has stated dcth needs a new trial?
At best they will get a refuse to accept the application to approve the device. has anyone thought this through?
what can the panel review? all we have is gen 1 trial data. we are back to square 1.
dcth has to raise more cash and start all over again.
I see this going much lower as the stock gets diluted with new massive stock offerings.